logo

EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link:  https://ebookbell.com/faq 


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Fast Facts: Non-Small-Cell Lung Cancer M. O'brien B. Besse M.m. Awad

  • SKU: BELL-43849634
Fast Facts: Non-Small-Cell Lung Cancer M. O'brien B. Besse M.m. Awad
$ 31.00 $ 45.00 (-31%)

4.7

26 reviews

Fast Facts: Non-Small-Cell Lung Cancer M. O'brien B. Besse M.m. Awad instant download after payment.

Publisher: Karger Medical and Scientific Publishers
File Extension: PDF
File size: 4.68 MB
Pages: 146
Author: M. O'Brien, B. Besse, M.M. Awad
ISBN: 9783318070880, 3318070882
Language: English
Year: 2022

Product desciption

Fast Facts: Non-Small-Cell Lung Cancer M. O'brien B. Besse M.m. Awad by M. O'brien, B. Besse, M.m. Awad 9783318070880, 3318070882 instant download after payment.

Despite an overall decrease in tobacco use, lung cancer (80–85% of which is non-small-cell lung cancer [NSCLC]) is still the leading cause of cancer death in both men and women worldwide. Annual low-dose CT screening of high-risk individuals has the potential to detect early-stage tumors, which can usually be successfully treated with a combination of surgery, radiotherapy, and chemotherapy and, in some cases, targeted therapy. However, most patients with NSCLC still present with advanced or metastatic disease. For these patients, initial therapy is guided by the tumor’s molecular characteristics and patient’s performance status. Targeted therapies have significantly improved clinical outcomes and, for some patients with no targetable genetic alterations, immunotherapy has demonstrated significant overall survival benefit. This insightful guide is designed to bring you up to speed with the latest developments and is important reading for all health professionals and medical trainees working in this fast-moving field. Table of Contents: • Prevention and screening • Diagnosis and staging • Surgery • Radiotherapy • Systemic therapy in non-metastatic NSCLC • Systemic therapy in advanced-stage/metastatic disease without a molecular driver • Personalized treatment in advanced NSCLC • Oligometastatic disease and brain metastases

Related Products